NEED TO REPLACE YOUR ANTIBODY SUPPLIER?
Upgrade to Bethyl | Learn More

Scientific Advisory Board
Bethyl’s Scientific Advisory Board (SAB) is currently comprised of the following nine members:

James Brugarolas, M.D., Ph.D.

Chair: James Brugarolas, M.D., Ph.D., Associate Professor at the University of Texas Southwestern Medical Center in the departments of Internal Medicine and Developmental Biology, Dallas TX.

Education
M.D., University of Navarra, Spain (1993) Ph.D., Massachusetts Institute of Technology, Cambridge, MA (1998) Internship & Residency in Internal Medicine: Duke University Center, Durham, NC (2001)
Fellowship in Medical Oncology: Dana-Farber Cancer Institute, Boston, MA (2003)

Dr. Brugarolas is the leader of the Kidney Cancer Program and co-leads the Cell Networks Scientific Program of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

Research Interests
Molecular genetics and biology of renal cell carcinoma

Christopher L. Corless, M.D., Ph.D.

Christopher L. Corless, M.D., Ph.D., Professor in Pathology at the Oregon Health & Science University (OHSU) and Chief Medical Officer for Knight Diagnostic Laboratories at OHSU, Portland, OR.

Education
M.D., Washington University School of Medicine, St. Louis, MO (1988)
Ph.D., Washington University School of Medicine, St. Louis, MO (1988)
Residency in Anatomic Pathology: Brigham and Women's Hospital, Boston, MA (1988-1990)
Fellowship in Gastrointestinal Pathology at Brigham and Women's Hospital, Boston, MA (1990-1992) and in Urologic Pathology at Brigham and Women’s Hospital, Boston, MA (1992-1993)

Research Interests
Molecular Pathology Applications

Zhijian Chen, Ph.D.

Zhijian Chen, Ph.D., George L. MacGregor Distinguished Chair in Biomedical Science, Professor in Molecular Biology at the University of Texas Southwestern Medical Center, Dallas, TX; Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD.

Education
Ph.D., State University of New York, Buffalo, NY

Research Interests
Ubiquitin, NF-κB pathway and antiviral signaling

Gordon Freeman, Ph.D.

Gordon Freeman, Ph.D., Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Education
Ph.D., Harvard University, Cambridge, MA (1979)
Fellowship in Molecular Immunology, Dana-Farber Cancer Institute, Boston, MA (1979-1984, 1985-1991)

Dr. Freeman’s research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).

Research Interests
Immune response regulatory checkpoints and their potential as therapeutic targets in cancer, chronic infections, and inflammatory disease
Jun Qin, Ph.D.

Jun Qin, Ph.D. Professor in Biochemistry and Molecular Biology, and Molecular and Cellular Biology at the Baylor College of Medicine, Houston, TX.

Education
Ph.D., The Rockefeller University, New York, NY (1996)

Research Interests
Mass spectrometry-based proteomic network analysis

Dr. David L. Rimm, M.D., Ph.D.

David L. Rimm, M.D., Ph.D. Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology at the Yale University of Medicine.

Education
M.D., John Hopkins University (1989)
Ph.D., John Hopkins University (1989)
Residency in Pathology: Yale-New Haven Hospital, New Haven, CT (1993)
Fellowship in Cytopathology: Medical College of Virginia, Richmond, MA (1994)

Dr. Rimm’s lab group focuses on quantitative pathology using the AQUA® technology, which was invented in his lab, with projects related to predicting response to therapy in breast cancer and predicting recurrence or metastasis in melanoma and lung cancer.

Research Interests
Pathology, cytopathology, breast cancer, melanoma, lung cancer, and molecular oncology and diagnostics

Dr. David Tuveson, M.D., Ph.D.

David Tuveson, M.D., Ph.D., Professor and Deputy Director of the Cancer Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Also, Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; and Director of Research for the Lustgarten Foundation.

Education
M.D., John Hopkins University, Baltimore, MD
Ph.D., John Hopkins University, Baltimore, MD (1994)
Residency: Brigham and Women’s Hospital, Boston, MA (1994-1997)
Fellowship in Medical Oncology Dana-Farber/Partners Cancer Care, Boston, MA (1997-2000)

Research Interests
Genetics, diagnostics and experimental therapeutics of pancreatic cancer

Thomas Westbrook, Ph.D.

Thomas Westbrook, Ph.D., Associate Professor in the departments of Biochemistry & Molecular Biology, and Molecular & Human Genetics at Baylor College of Medicine, Houston, TX.

Education
Ph.D., University of Rochester School of Medicine, Rochester, NY (2003)
Postdoctoral fellow, Harvard Medical School, Boston, MA (2003-2007)

Dr. Westbrook leads a research team in breast cancer genetics and genomics and is an American Cancer Society Scholar and a DOD Era of Hope Scholar in breast cancer research.

Research Interests
RNA interference technologies, cancer genes and networks, and cancer therapies

Hongtao Yu, Ph.D.

Hongtao Yu, Ph.D., Professor of Pharmacology at University of Texas Southwestern Medical Center, Dallas, TX; Investigator, Howard Hughes Medical Institute (HHMI), Chevy Chase, MD.

Education
Ph.D. in Chemistry, Harvard University, Cambridge, MA (1995)
Postdoc in Cell Biology, Harvard Medical School, Boston, MA (1995-1999)

Research Interests
Chromosome Segregation; Mitosis; Histone Modifications; DNA Repair; Protein Structure